公开(公告)号：WO2016081534A1

公开(公告)日：2016-05-26

申请号：PCT/US2015/061215

申请日：2015-11-18

Applicant: METABOLON, INC.

Inventor： PERICHON, Regis ,  BELL, Lauren, Nicole ,  WULFF, Jacob ,  NGUYEN, Uyen, Thao ,  WATKINS, Steven, M.

IPC: C12Q1/00 ,  G01N33/50 ,  G01N33/68

CPC classification number: G01N33/92 ,  G01N33/50 ,  G01N33/5023 ,  G01N33/6806 ,  G01N33/82 ,  G01N2560/00 ,  G01N2570/00 ,  G01N2800/085 ,  G01N2800/56 ,  G01N2800/7052

Abstract: Biomarkers of NASH, NAFLD, and fibrosis and methods for diagnosis (or aiding in the diagnosis) of NAFLD, NASH and/or fibrosis are described herein. Additionally, methods of distinguishing between NAFLD and NASH, methods of classifying the stage of fibrosis, methods of determining the severity of liver disease, methods of determining the severity of liver disease or fibrosis, and methods of monitoring progression/regression of NASH, NAFLD, and/or fibrosis are described herein.

Abstract translation: 本文描述了NASH，NAFLD和纤维化的生物标志物和NAFLD，NASH和/或纤维化的诊断（或辅助诊断）的方法。 另外，区分NAFLD和NASH的方法，分类纤维化阶段的方法，确定肝脏疾病严重程度的方法，确定肝病或纤维化严重程度的方法，以及监测NASH，NAFLD， 和/或纤维化。

公开(公告)号：WO2015157407A8

公开(公告)日：2015-10-15

申请号：PCT/US2015/024907

申请日：2015-04-08

Applicant: METABOLON, INC.

Inventor： MILBURN, Michael, V. ,  RYALS, John, A. ,  GUO, Lining ,  ECKHART, Andrea ,  WULFF, Jacob ,  KENNEDY, Adam, D. ,  JÖNSSON, Thomas, J. ,  MICHALEK, Ryan, Douglas ,  WITTMANN, Bryan ,  MITCHELL, Matthew

IPC: G06F19/28 ,  G01N33/50

Abstract: Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

公开(公告)号：WO2017079384A1

公开(公告)日：2017-05-11

申请号：PCT/US2016/060245

申请日：2016-11-03

Applicant: METABOLON, INC.

Inventor： KENNEDY, Adam, D. ,  MITCHELL, Matthew, W. ,  BROWN, Meredith, V. ,  LAWTON, Kay, A. ,  LONERGAN, Shaun ,  WULFF, Jacob

IPC: G06F19/28 ,  G06F19/10 ,  G01N33/50 ,  G01N33/48

CPC classification number: G01N33/48 ,  G01N33/50 ,  G01N33/5308 ,  G01N33/66 ,  G01N33/68 ,  G01N33/92 ,  G06F19/10 ,  G06F19/28

Abstract: A method of assessing the quality of a biological sample while maintaining the viability of the biological sample for intended use analysis is described herein. The method includes analyzing a biological sample obtained from a subject for an intended use, assessing the quality of the biological sample using one or more biomarkers of sample quality, and simultaneously performing intended use analysis on the same sample. Assessing the quality of the sample can include assessing compliance with sample handling protocols and assessing subject compliance.

Abstract translation: 本文描述了评估生物样品质量同时保持生物样品用于预期用途分析的生存力的方法。 该方法包括分析从受试者获得的预期用途的生物样品，使用一种或多种样品质量的生物标记评估生物样品的质量，并同时对相同样品进行预期的使用分析。 评估样本的质量可以包括评估样本处理协议的遵守情况和评估受试者的依从性。